- Home
- BCML vs MNPR Comparison
BCML vs MNPR Comparison
Compare BCML & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCML | MNPR |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.6M | 368.9M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BCML | MNPR |
|---|---|---|
| Price | $29.03 | $52.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $34.00 | ★ $107.00 |
| AVG Volume (30 Days) | 30.6K | ★ 168.2K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | 3.81 | ★ 54.99 |
| EPS | ★ 2.18 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.71 | N/A |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $13.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.15 | $28.40 |
| 52 Week High | $33.15 | $105.00 |
Technical Indicators
Market Signals| Indicator | BCML | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 39.60 |
| Support Level | $27.42 | $50.77 |
| Resistance Level | $29.44 | $60.67 |
| Average True Range (ATR) | 1.02 | 3.36 |
| MACD | -0.09 | -0.25 |
| Stochastic Oscillator | 31.77 | 24.77 |
Price Performance
Historical ComparisonAbout BCML BayCom Corp
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses, and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services. The Company operates as one reportable segment: banking operations.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.